El valor de la selección de pacientes en NSCLC: tratamiento de segunda línea en pacientes PD-L1 positivo - page 27

PD-L1 Expression Continuum and Response
Probability
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
27
Based on a March 18, 2015 database lock
aLogistic regression models with baseline PD-L1 expression as continuous covariate
9 31 37 41 15 12 13 7
100
80
20
60
0
40
Baseline PD-L1 expression level
<1% ≥1% ≥50% ≥10%
10/108 n/N 15/101 38/123 15/123 32/86 10/79 27/66 3/46
ORR (%) [95% CI]
Nivolumab
Docetaxel
Estimated response probability
a
(%)
Baseline PD-L1 expression level (%)
100
75
25
50
0
1 100 10 20 30 40 50 60 70 80 90
95% CI
95% CI
Nivolumab (n = 121)
Docetaxel (n = 115)
Estimateda